- Home
- CGEN
CGEN
Compugen Ltd.
as 02-21-2025 4:00pm EST
| Founded: | 1993 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2000 |
| Target Price: | $4.00 | AVG Volume (30 days): | 637.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.35 - $3.03 | Next Earning Date: | 03-04-2025 |
| Revenue: | $59,852,000 | Revenue Growth: | 698.03% |
| Revenue Growth (this year): | 34.22% | Revenue Growth (next year): | -23.72% |
Latest Compugen Ltd. News
CGEN Breaking Stock News: Dive into CGEN Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
PR Newswire
19 days ago
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PR Newswire
a month ago
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Simply Wall St.
2 months ago
The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable
PR Newswire
3 months ago
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Simply Wall St.
3 months ago
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
GuruFocus.com
3 months ago
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...
Zacks
3 months ago
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
Compare CGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGEN Compugen Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.